Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin vs Glimepiride on Endothelial Dysfunction in T2DM
NCT02301806Phase 4Unknown
- Sponsor
- Dokkyo Medical University
- Start
- Jan 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dokkyo Medical University. Primary endpoint: Flow-mediated vasodilatation at 12 weeks. Status: unknown.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02301806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02301806.